Improved Transparency In Europe: TTIP And Trade Secrets Legislation Could Hold Back Progress In 2015
Executive Summary
Castigated for not providing public access to clinical trial data nor details of a proposed free trade deal with the U.S., the European Commission and national regulatory agencies will push transparency this year. But pending legislation on trade secrets, data protection and trademarks could hold back progress in this arena.
You may also be interested in...
EMA Leadership Goes To Pott After Rasi Retroactively Unhired
Andreas Pott, who helped steer agency through Mediator scandal, becomes acting director again as irregularities in 2011’s recruitment process force departure of Guido Rasi – who himself might still get top job again once hiring process reboots.
MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.